Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Johns Hopkins Medical Institutions, Baltimore, Maryland, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Baltimore, Maryland
Treatments:ChemotherapyHospital:Johns Hopkins Medical Institutions
Drugs:Journal:Link
Date:Mar 2002

Description:

Patients: This Phase II study involved 42 patients with androgen independent prostate cancer. The median age was 68 years. Sites of metastasis included bone, soft tissue, and lymph nodes. Prior therapies included: prostatectomy, radiotherapy, and hormonal therapy.

Treatment: The treatment consisted of the administration of two chemotherapy drugs docetaxel (taxotere) and estramustine (emcyt).

Toxicity: Grade 4 toxicities included leucopenia, neutropenia, and one patient developed atrial fibrillation with congestive heart failure. (This patient had no documented history of prior cardiac problems.)

Results: The median survival for all patients was 13.5 months.

Support: The study was supported by Aventis Pharmaceuticals. In addition, half of the study’s authors (3 of 6) are members of the Advisory Board and the Speaker’s Bureau for Aventis. Aventis markets taxotere.




Back